Astrocytic Hevin/ SPARCL ‐1 Regulates Cognitive Decline in Pathological and Normal Brain Aging
Aging Cell · 2025-05 · 24 (5)
DOI: 10.1111/acel.14493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, online erschienen am 12.02.2025. Verfasst von Felipe Cabral-Miranda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Astrocytes, Aging, Brain, Cognitive Dysfunction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Departamento de Ciência e Tecnologia, Ministério da Saúde (Decit-MS), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).
Abstract (Originalsprache)
Dementia, characterized by loss of cognitive abilities in the elderly, poses a significant global health challenge. This study explores the role of astrocytes, one of most representative glial cells in the brain, in mitigating cognitive decline. Specifically, we investigated the impact of Hevin (also known as SPARC‐like1/SPARCL‐1), a secreted glycoprotein, on cognitive decline in both normal and pathological brain aging. By using adeno‐associated viruses, we overexpressed Hevin in hippocampal astrocytes of middle‐aged APP/PSEN mice, an established Alzheimer's disease (AD) model. Results demonstrated that Hevin overexpression attenuates cognitive decline, as evidenced by cognitive tests, increased pre‐ and postsynaptic markers colocalization, and altered expression of synaptic mediators, as revealed by proteomic profiling. Importantly, Hevin overexpression did not influence the deposition of Aβ plaques in the hippocampus, a hallmark of AD pathology. Furthermore, the study extended its findings to middle‐aged wild‐type animals, revealing improved cognitive performance following astrocytic Hevin overexpression. In conclusion, our results propose astrocytic Hevin as a potential therapeutic target for age‐associated cognitive decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Sciences, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
- Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
ORCID-Profile: Felipe Cabral-Miranda, Ana Paula Bergamo Araujo, Danilo Bilches Medinas, Flávia Carvalho Alcantara Gomes
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Departamento de Ciência e Tecnologia, Ministério da Saúde (Decit-MS)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
- Fiocruz-MS-Servier Award
- Instituto Nacional de Neurociência Translacional (INCT-INNT)
- São Paulo Research Foundation (FAPESP)
- Instituto Nacional de Ciência e Tecnologia de Neurociência Translacional
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Cabral-Miranda, F., Araujo, A. P. B., Medinas, D. B., & Gomes, F. C. A. (2025). Astrocytic Hevin/ SPARCL ‐1 Regulates Cognitive Decline in Pathological and Normal Brain Aging. Aging Cell, 24(5). https://doi.org/10.1111/acel.14493
Vancouver
Cabral-Miranda F, Araujo APB, Medinas DB, Gomes FCA. Astrocytic Hevin/ SPARCL ‐1 Regulates Cognitive Decline in Pathological and Normal Brain Aging. Aging Cell. 2025;24(5). doi:10.1111/acel.14493
BibTeX
@article{CabralMiranda2025,
author = {Cabral-Miranda, Felipe and Araujo, Ana Paula Bergamo and Medinas, Danilo Bilches and Gomes, Flávia Carvalho Alcantara},
title = {Astrocytic Hevin/ SPARCL ‐1 Regulates Cognitive Decline in Pathological and Normal Brain Aging},
journal = {Aging Cell},
year = {2025},
volume = {24},
number = {5},
doi = {10.1111/acel.14493}
}
EUVIMED